Barclays
SYRS

Barclays’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Barclays’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-935
Closed -$11K – 5319
2022
Q1 		$11K Sell
935
-6,053
-87% -$108K ﹤0.01% 4592
2021
Q4 		$228K Buy
6,988
+2,502
+56% +$101K ﹤0.01% 3518
2021
Q3 		$200K Sell
4,486
-1,390
-24% -$67.9K ﹤0.01% 3627
2021
Q2 		$320K Sell
5,876
-1,828
-24% -$108K ﹤0.01% 3320
2021
Q1 		$577K Buy
7,704
+6,330
+461% +$658K ﹤0.01% 3105
2020
Q4 		$150K Sell
1,374
-531
-28% -$48.5K ﹤0.01% 3936
2020
Q3 		$168K Sell
1,905
-383
-17% -$43.5K ﹤0.01% 3955
2020
Q2 		$244K Buy
2,288
+1,139
+99% +$102K ﹤0.01% 3913
2020
Q1 		$68K Sell
1,149
-2,408
-68% -$163K ﹤0.01% 5031
2019
Q4 		$245K Buy
3,557
+1,768
+99% +$107K ﹤0.01% 4881
2019
Q3 		$185K Sell
1,789
-446
-20% -$42.1K ﹤0.01% 5031
2019
Q2 		$207K Buy
2,235
+1,490
+200% +$104K ﹤0.01% 5071
2019
Q1 		$68K Buy
745
+452
+154% +$31.5K ﹤0.01% 5670
2018
Q4 		$17K Sell
293
-964
-77% -$73.2K ﹤0.01% 5981
2018
Q3 		$150K Buy
1,257
+1,078
+602% +$125K ﹤0.01% 5224
2018
Q2 		$18K Sell
179
-142
-44% -$17.6K ﹤0.01% 6250
2018
Q1 		$41K Buy
321
+123
+62% +$13.4K ﹤0.01% 6038
2017
Q4 		$19K Buy
198
+159
+408% +$21.4K ﹤0.01% 6315
2017
Q3 		$5K Buy
39
+38
+3,800% +$7.15K ﹤0.01% 6434
2017
Q2 		$0 Sell
1
-1
-50% -$157 ﹤0.01% 6996
2017
Q1 		$0 Sell
2
-1
-33% -$122 ﹤0.01% 7031
2016
Q4 		$0 Sell
3
-34
-92% -$4.77K ﹤0.01% 6881
2016
Q3 		$5K Buy
+37
New +$4.7K ﹤0.01% 6031

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's SYRS Position: Q2 2022 in Review

Barclays sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 935 shares — an estimated $11K sold.

Barclays first reported a position in SYRS in Q3 2016 and held it in 23 quarters. The position peaked at $577K in Q1 2021. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

  • Barclays reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 935 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $11K.
  • Barclays first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 23 quarters.
  • Barclays's Syros Pharmaceuticals, Inc. Common Stock position peaked at $577K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.